RecruitingPhase 4NCT06562816

Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain

Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain: a Randomized Controlled Trial

Sponsor

Dow University of Health Sciences

Enrollment

100 participants

Start Date

Aug 16, 2024

Study Type

INTERVENTIONAL

Conditions

Effect of Drug

Summary

This study aims to compare the pain reduction efficacy of Trypsin-Chymotrypsin and Naproxen sodium after root canal treatment in patients with symptomatic irreversible pulpitis. A lot of patients suffer greatly from post endodontic treatment pain and have a fear of dental treatments due to the pain. Patients refuse to go to the dentists and neglect oral hygiene care. That's why it is very important to find an effective drug regimen to reduce this post treatment pain. The null hypothesis is that there will be no difference between the efficacy and mean pain scores of Trypsin-chymotrypsin and Naproxen Sodium for post-endodontic treatment pain. Conducted as a triple-blinded, parallel, randomized controlled trial, 100 patients will be randomly assigned to receive either Trypsin-Chymotrypsin or Naproxen sodium following standard root canal therapy. Pain levels will be assessed using a numerical rating scale at 1, 6, 12, and 24 hours post-treatment to evaluate the effectiveness of these two pain management modalities.

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

Both male and female, healthy patients (ASA class 1).
Patients between the age group of 18-45 years.
Patients who are appointed for endodontic treatment.
Maxillary or mandibular teeth diagnosed with symptomatic irreversible pulpitis based on delayed responses to vitality tests.

Exclusion Criteria6

Patients who will require emergency dental treatment.
Teeth with any form of peri-apical lesion will be excluded.
Patient who have taken analgesics within 24 hours prior to the treatment.
Patients with known hypersensitivity or allergy to any of the study medications.
Patients with any systemic disease such as uncontrolled diabetes, gastric ulcers, bleeding disorders, or cardiovascular problems.
Pregnant or lactating women and pediatric patients.